Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5232701 | 0.94 | ABCC2 (0.32) | NPSR1L3MBTL1NOS1 | |
| SCHEMBL13501610 | 0.90 | ESR1 (0.32) | ESR1PTGS1PDE4A | |
| SCHEMBL8226967 | 0.90 | ESR1 (0.32) | ESR1PTGS1PDE4A | |
| Iodide SCHEMBL5235454 | 0.89 | ESR1 (0.32) | ESR1PTGS1PDE4A | |
| SCHEMBL13946392 | 0.88 | ESR1 (0.31) | ESR1PTGS1PDE4A | |
| SCHEMBL5235538 | 0.87 | ESR1 (0.37) | ESR1PTGS1PDE4A | |
| SCHEMBL304850 | 0.84 | ABCC2 (0.31) | — | |
| SCHEMBL29597347 | 0.84 | ABCC2 (0.31) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL5238034 | 0.83 | ESR1 (0.32) | ESR1PTGS1PDE4A | |
| SCHEMBL5237918 | 0.83 | ABCC2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1336612-B1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-6908913-B2 | Carbapenem derivatives | MEIJI SEIKI KAISHA, LTD. (JP) | 2005-06-21 | — | — | US | disclosed |
| US-20040038967-A1 | Novel carbapenem derivatives | MEIJI SEIKI KAISHA, LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1336612-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038967-A1 | Novel carbapenem derivatives | DHPS, HAMP, MCRS1 | NPSR1 631/4885L3MBTL1 2591/4885ESR1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.